Nkarta (NKTX) Osake Kurssi

Nkarta Inc is primarily active in the biotechnology industry.

The main competitors of Nkarta Inc in the market are Adaptimmune Therapeutics, bluebird bio, and Celgene Corporation.

Nkarta Inc, a biotechnology company founded in 2015, focuses on developing cellular therapies for cancer treatment. With headquarters in South San Francisco, California, Nkarta operates with a vision to harness the power of the body's immune system to combat cancer effectively. The company specializes in natural killer (NK) cells, which play a crucial role in protecting against tumor growth. Leveraging their proprietary technology, Nkarta engineers enhanced NK cells, known as NKT cells, to enhance their potency and persistence. As a prominent player in the field of cellular immunotherapy, Nkarta Inc strives to advance innovative treatments and improve outcomes for patients battling various cancers.

Nkarta Inc, a leading biotechnology company, has achieved several significant milestones. Firstly, they successfully completed their IPO in 2020, raising substantial capital to fund their ongoing research and development efforts. Additionally, Nkarta has made remarkable progress in advancing their pipeline of novel natural killer (NK) cell therapies. They have received clearance from the FDA for their Investigational New Drug (IND) application, allowing them to initiate clinical trials. Nkarta has also forged strategic collaborations with renowned institutions, further reinforcing their expertise and expanding their reach in the field of cell therapies. These milestones demonstrate Nkarta Inc's commitment to revolutionizing cancer treatment through innovative therapies harnessing the power of NK cells.

Nkarta Inc is primarily present in the United States.

Nkarta Inc represents a strong set of values and corporate philosophy. As a biotechnology company, Nkarta Inc is committed to transforming the lives of patients with complex diseases by harnessing the power of natural killer (NK) cells. The company believes in scientific innovation and collaboration to develop groundbreaking therapies. Nkarta Inc is devoted to delivering effective and safe treatments while maintaining the highest ethical standards. With a passion for improving patient outcomes, Nkarta Inc strives to be a leader in the biotech industry by driving advancements in cell therapy.

13 analyytikkoa arvioi tällä hetkellä Nkarta-osaketta: 12 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Nkarta-yhtiöltä 2,25 M USD liikevaihtoa ja −1,60 USD osakekohtaista tulosta.

Nkarta Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Nkarta-osake noteerataan hintaan 1,60 EUR (1,80 USD).

Nkarta-osake (NKTX) on listattuna 1 pörssissä, muun muassa: NASDAQ (NKTX).

Nkarta Inc is a biotechnology company specializing in developing innovative and personalized therapies for cancer patients based on natural killer cells (NK cells). The company has a business model that spans multiple sectors and offers a wide range of products and services. The first sector of Nkarta is the research and development of personalized NK cell therapies for cancer patients. NK cells are part of the innate immune system and can directly attack and kill cancer cells. Nkarta utilizes advanced technologies such as CRISPR/Cas9 genome editing and CAR (chimeric antigen receptor)-based NK cell therapies to enhance the effectiveness of NK cells. The company is working on developing therapies for various types of cancer, including leukemia, lymphoma, and solid tumors. The second sector of Nkarta is the manufacturing and provision of NK cell products for clinical studies. Nkarta has its own production facility that is GMP certified and meets the highest quality standards. The company offers customers a wide range of products such as natural killer cells (NK cells) obtained from the patient's blood or donor blood, CAR NK cells, as well as specialized devices and consumables. The third sector of Nkarta is collaboration with other companies and institutions in the development of personalized NK cell therapies. Nkarta works with various partners to accelerate the development of NK cell therapies and improve the effectiveness of NK cells in cancer therapy. The company recently partnered with CRISPR Therapeutics to further develop its CAR NK cell technology and conduct clinical studies. In addition to these sectors, Nkarta is also active in the field of financing. The company has conducted several funding rounds, raising over $100 million. These funds are used to finance research and development, manufacturing of NK cell products, and expansion of business operations. In summary, Nkarta offers a wide range of products and services in the field of personalized NK cell therapy. The company has a comprehensive business model that spans multiple sectors, including research and development, manufacturing of NK cell products, collaboration with partners, and financing. Thanks to its innovative technologies and highly skilled employees, Nkarta is well-positioned to offer its customers effective and personalized cancer treatment.

odotettu liikevaihto Nkarta on 2,25 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Nkarta on −118,50 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Nkarta:n hinta-voitto-suhde (P/E) on tällä hetkellä −1,12. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Nkarta-osakkeen arvostusta.

Nkarta:n hinta-myynti-suhde (P/S) on tällä hetkellä 59,24. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Nkarta-osakkeen arvostuskennuslukuna.

Nkarta:n Eulpool-laatuscore on 2/10.

Nkarta:n ISIN on US65487U1088. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Nkarta:n WKN on A2P797. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Nkarta:n ticker on NKTX. Tämä pörssinoteeraus käytetään Nkarta-osakkeiden kauppaan pörssissä.